Journal
VACCINES
Volume 10, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/vaccines10111884
Keywords
malaria; vaccine; axenic liver stage; subcutaneous immunization; Plasmodium yoelii
Categories
Funding
- TUBITAK 1001 grant from the Scientific and Technological Research Council of Turkey [119Z409]
Ask authors/readers for more resources
The study demonstrates that axenic liver stages serve as a novel live whole parasite malaria vaccine platform, providing effective protection through subcutaneous immunization without infecting the host.
Host cell-free, axenic development of liver stages (LS) of the malaria parasite has been demonstrated. Here we explored axenic liver stages as a novel live whole parasite malaria vaccine platform, which is unaltered and not prone to human-error, compared to the immunization with live-attenuated sporozoites that must be done intravenously. We show that in contrast to live sporozoites, axenic LS are not infectious to the immunized host. Subcutaneous immunizations of mice with Plasmodium yoelii axenic LS, developed from wild-type (WT) sporozoites or WT sporozoites expressing enhanced-GFP, conferred sterile protection against P. yoelii infectious sporozoite challenge. Thus, axenic liver stages of P. falciparum and P. vivax might constitute an attractive alternative to live sporozoite immunization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available